Dr. Iazsmin Bauer Ventura is a faculty member of the Section of Rheumatology at the University of Chicago, an expert in the care of patients with idiopathic inflammatory myopathies or myositis (IIM) and interstitial lung diseases (ILD). Dr. Bauer Ventura is the director of the multidisciplinary Myositis Program at the University of Chicago, encompassing specialists in Neurology, Pulmonary, and Dermatology, who provide comprehensive care to individuals carrying the diagnosis of dermatomyositis, anti-synthetase syndrome, autoimmune necrotizing myopathy, inclusion body myositis, and polymyositis. She has served in several international committees and worked in projects devoted to improving the diagnosis and treatment of individuals of myositis. Her clinical research has focused on clinical trials for patients with myositis, including cell therapy such as CAR-T cells.
Dr. Bauer Ventura is also a member of the multidisciplinary interstitial lung disease (ILD) group at the University of Chicago and hosts a combined rheumatology-pulmonary clinic dedicated to patients with ILD due to autoimmune diseases. The ILD Program at the University of Chicago has been internationally recognized for its innovative and collaborative clinical research in ILD and also provides clinical trials for these diseases.
Dr. Bauer Ventura has been awarded for her clinical care and also works as an educator to trainees.
Transcriptomic Profiling of Long COVID in Interstitial Lung Disease Patients Reveals Dysregulation of Mitochondrial Oxidative Phosphorylation.
Transcriptomic Profiling of Long COVID in Interstitial Lung Disease Patients Reveals Dysregulation of Mitochondrial Oxidative Phosphorylation. Am J Respir Cell Mol Biol. 2025 Apr 30.
PMID: 40305670
Clinical Characteristics of Anti-Synthetase Syndrome: Analysis From the Classification Criteria for Anti-Synthetase Syndrome Project.
Clinical Characteristics of Anti-Synthetase Syndrome: Analysis From the Classification Criteria for Anti-Synthetase Syndrome Project. Arthritis Rheumatol. 2025 Apr; 77(4):477-489.
PMID: 39467037
Interstitial Lung Disease in Firefighters: An Emerging Occupational Hazard.
Interstitial Lung Disease in Firefighters: An Emerging Occupational Hazard. Front Med (Lausanne). 2022; 9:864658.
PMID: 35386918
High-titer rheumatoid factor seropositivity predicts mediastinal lymphadenopathy and mortality in rheumatoid arthritis-related interstitial lung disease.
High-titer rheumatoid factor seropositivity predicts mediastinal lymphadenopathy and mortality in rheumatoid arthritis-related interstitial lung disease. Sci Rep. 2021 11 24; 11(1):22821.
PMID: 34819525
Rituximab for interstitial pneumonia with autoimmune features at two medical centres.
Rituximab for interstitial pneumonia with autoimmune features at two medical centres. Rheumatol Adv Pract. 2021 Nov; 5(Suppl 2):ii1-ii9.
PMID: 34755024
Characteristics and Prevalence of Domestic and Occupational Inhalational Exposures Across Interstitial Lung Diseases.
Characteristics and Prevalence of Domestic and Occupational Inhalational Exposures Across Interstitial Lung Diseases. Chest. 2021 07; 160(1):209-218.
PMID: 33621598
COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia.
COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia. Clin Pharmacol Ther. 2021 03; 109(3):688-696.
PMID: 33210302
Association of Black Race with Outcomes in COVID-19 Disease: A Retrospective Cohort Study.
Association of Black Race with Outcomes in COVID-19 Disease: A Retrospective Cohort Study. Ann Am Thorac Soc. 2020 10; 17(10):1336-1339.
PMID: 32643398
COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19.
COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19. medRxiv. 2020 Jul 26.
PMID: 32743594
Effects of deep sedation on sleep in critically ill medical patients on mechanical ventilation.
Effects of deep sedation on sleep in critically ill medical patients on mechanical ventilation. J Sleep Res. 2020 06; 29(3):e12894.
PMID: 31352685